What Is RT GLP3? A Complete Guide to the Triple Receptor Agonist

Last reviewed: July 2026

RT GLP3 is an investigational peptide being studied for obesity, type 2 diabetes and other conditions linked to excess body fat and metabolic dysfunction.

It has attracted considerable scientific attention because it activates three hormone receptors involved in appetite, blood-glucose regulation and energy metabolism:

• Glucose-dependent insulinotropic polypeptide, or GIP

• Glucagon-like peptide-1, or GLP-1

• Glucagon

This three-part mechanism is why RT GLP3 is often described as a triple receptor agonist.

Earlier medicines generally targeted one of these pathways, while newer treatments began combining two. RT GLP3 goes a step further by incorporating glucagon-receptor activity alongside GIP and GLP-1 receptor activation.

Clinical research has reported substantial reductions in body weight, blood glucose and several markers of metabolic health. However, RT GLP3 remains an investigational medicine. As of July 2026, it has not been approved for routine medical use in the United Kingdom.

This guide explains what RT GLP3 is, how its three-part mechanism works, how it differs from semaglutide and TZ GLP1, and what researchers have learned from clinical trials so far.

RT GLP3, previously known by the development code LY3437943, is a synthetic peptide developed by Eli Lilly and Company.

It was designed to reproduce selected actions of three naturally occurring hormones:

1. GIP

2. GLP-1

3. Glucagon

These hormones form part of the communication network connecting the digestive system, pancreas, liver, fat tissue and brain.

After food is eaten, the body releases chemical signals that help it:

• Respond to rising blood glucose

• Release insulin when appropriate

• Regulate hunger and fullness

• Control the movement of food through the stomach

• Decide whether nutrients should be stored or used for energy

• Maintain energy availability between meals

RT GLP3 does not simply copy one natural hormone. Its structure has been engineered to activate all three target receptors within a single molecule.

It is therefore better described as a multi-receptor metabolic agonist than simply as another GLP-1 compound.

A receptor is a specialised structure found on or inside a cell. It receives chemical signals and triggers a response within that cell.

An agonist is a substance that binds to a receptor and activates it.

A simple comparison is to think of a receptor as a lock and an agonist as a key. When the correct key interacts with the lock, it switches on a biological process.

RT GLP3 has been designed to interact with three related but distinct locks:

• The GIP receptor

• The GLP-1 receptor

• The glucagon receptor

Activating three receptors does not mean that all three produce the same effect. Each pathway contributes something different to the overall metabolic response.

Understanding those differences is central to understanding why RT GLP3 was developed.

How does RT GLP3 work?

RT GLP3 combines the effects of GIP, GLP-1 and glucagon receptor activation. Researchers are investigating whether these pathways can complement and balance one another.

Its effects cannot be reduced to a single action such as appetite suppression. The compound may influence several connected processes, including:

• Hunger and satiety signalling

• Insulin secretion

• Blood-glucose regulation

• Stomach emptying

• Energy expenditure

• Fat use and storage

• Liver fat

• Wider cardiometabolic health

The contribution of each receptor is explained below.

GLP-1 is an incretin hormone released mainly by specialised cells in the intestine after food is consumed.

An incretin is a gut-derived hormone that helps the body respond to nutrients. One of its most important functions is supporting insulin secretion when blood glucose is elevated.

GLP-1 receptor activation can affect several systems.

GLP-1 signalling communicates with regions of the brain involved in appetite. This can increase feelings of fullness and reduce the drive to continue eating.

This is not simply a matter of making food physically less appealing. GLP-1-related signalling can change the biological feedback involved in hunger, meal size and satiety.

GLP-1 supports glucose-dependent insulin secretion. In simple terms, it helps the pancreas release insulin when blood glucose is elevated.

Because this response is linked to glucose availability, it differs from continuously forcing insulin release regardless of blood-glucose level.

GLP-1 can reduce inappropriate glucagon secretion when blood glucose is elevated. This may help limit unnecessary glucose release from the liver after eating.

GLP-1 receptor activation can slow the rate at which food leaves the stomach, particularly during the earlier stages of treatment.

This may contribute to prolonged fullness, but it also helps explain why nausea, abdominal discomfort and other digestive effects can occur.

GLP-1 receptor agonism is the principal mechanism used by semaglutide. RT GLP3 includes this pathway but does not rely on it alone.

GIP is another incretin hormone released from the intestine in response to nutrients, particularly carbohydrates and fats.

Like GLP-1, it supports insulin secretion when blood glucose is elevated. Its wider role in body-weight regulation is more complicated.

Historically, some researchers questioned whether activating the GIP receptor would be useful in obesity because GIP is involved in nutrient handling and fat-tissue biology. However, clinical results with dual GIP and GLP-1 receptor agonists demonstrated that the combination could produce substantial improvements in glucose regulation and body weight.

Researchers continue to investigate exactly how GIP receptor activation contributes to these effects.

Possible functions include:

• Supporting glucose-dependent insulin secretion

• Modifying how fat tissue responds to nutrients

• Influencing appetite and food intake

• Improving the tolerability or effectiveness of combined receptor activation

• Working with GLP-1 signalling rather than acting independently

The success of TZ GLP1, which activates GIP and GLP-1 receptors, helped establish combined incretin-receptor agonism as an important area of metabolic research.

RT GLP3 retains these two pathways and adds glucagon-receptor activation.

Glucagon is often described as the hormone that opposes insulin.

When blood glucose becomes low, glucagon signals the liver to release stored glucose and produce additional glucose. This helps protect the body from inadequate energy availability between meals.

At first, activating the glucagon receptor might appear unhelpful in a compound being investigated for diabetes or obesity. Glucagon can raise blood glucose, which would seem to conflict with the aim of improving glucose control.

However, glucagon biology is more complex than this single effect.

Glucagon-receptor activation may also influence:

• Energy expenditure

• Fat oxidation

• Liver metabolism

• Amino-acid metabolism

• Nutrient availability

• Food intake

Researchers believe that carefully balanced glucagon activity may increase energy use and encourage the mobilisation of stored energy.

The GLP-1 and GIP components may help offset glucagon’s tendency to raise blood glucose by supporting insulin secretion and improving wider glucose regulation.

The aim is therefore not to maximise glucagon activity. It is to combine a controlled level of glucagon-receptor activation with complementary incretin effects.

This balance is one of the defining features of RT GLP3.

Why combine all three receptors?

Human metabolism is controlled by an interconnected network rather than one isolated hormone.

A treatment acting only through appetite reduction may not have the same effects as one that also influences:

• Insulin secretion

• Glucose production

• Energy expenditure

• Fat metabolism

• Liver fat

• Nutrient partitioning

RT GLP3 was designed around the idea that several coordinated mechanisms may produce a broader metabolic response than one pathway alone.

The proposed roles can be simplified as follows:

This table is necessarily simplified. The receptors interact with multiple organs, and their combined effects cannot be predicted by adding three isolated lists together.

The final response depends on the strength, balance and duration of activity at each receptor.

Is RT GLP3 an incretin?

RT GLP3 is frequently grouped with incretin-based medicines because it activates the receptors for GIP and GLP-1, both of which are incretin hormones.

However, glucagon is not normally classified as an incretin.

For that reason, descriptions such as triple hormone-receptor agonist or GIP, GLP-1 and glucagon receptor agonist are more precise than calling RT GLP3 a triple incretin.

The phrase “triple incretin” is commonly used informally, but it does not fully describe the glucagon component.

RT GLP3 compared with semaglutide and TZ GLP1

RT GLP3, TZ GLP1 and semaglutide belong to the same broad area of metabolic medicine, but they are not interchangeable.

Their main mechanistic difference is the number of receptors they are designed to activate.

Semaglutide is a GLP-1 receptor agonist.

Depending on the product and indication, semaglutide is approved for conditions including type 2 diabetes, weight management and cardiovascular-risk reduction in certain populations.

Its effects are produced primarily through GLP-1 receptor activation.

TZ GLP1 activates both GIP and GLP-1 receptors.

It is therefore called a dual receptor agonist. The addition of GIP receptor activity distinguishes it from semaglutide.

RT GLP3 activates GIP, GLP-1 and glucagon receptors.

Its glucagon component is the most important mechanistic difference from TZ GLP1.

However, the comparison is not simply “one receptor versus two versus three.” The strength of activity at each receptor, molecular structure, exposure and biological balance also differ.

A compound targeting more receptors is not automatically safer, more suitable or more effective for every person.

Direct comparisons require randomised head-to-head trials rather than assumptions based only on receptor count.

A Phase 3 study comparing RT GLP3 with TZ GLP1 in adults with obesity has been registered, but complete results are not yet available.

How long does RT GLP3 remain active?

Early clinical pharmacology research reported an average elimination half-life of approximately six days.

A half-life is the time required for the amount of a substance in the body to fall by approximately half.

A six-day half-life supports the once-weekly schedule being investigated in clinical trials. It also means RT GLP3 does not disappear from the body immediately after a dose.

Repeated administration can lead to accumulation until a relatively stable average exposure is reached.

The half-life should not be interpreted as a guarantee that every biological effect lasts exactly six days. Drug concentration, receptor activation, individual physiology and treatment duration can all affect the observed response.

What did the Phase 2 obesity trial investigate?

A major Phase 2 trial evaluated RT GLP3 in adults with obesity or overweight who did not have type 2 diabetes.

The study included 338 participants and compared several RT GLP3 regimens with placebo over 48 weeks.

The primary outcome was the percentage change in body weight at 24 weeks. Researchers also assessed:

• Body-weight change at 48 weeks

• The proportion of participants reaching different weight-loss thresholds

• Waist circumference

• Cardiometabolic markers

• Safety

• Treatment discontinuations

• Adverse events

The results showed a dose-dependent pattern: groups receiving higher target doses generally experienced greater average reductions in body weight.

At 48 weeks, the published mean changes included:

• 17.1% reduction in the combined 4 mg group

• 22.8% reduction in the 8 mg group

• 24.2% reduction in the 12 mg group

• 2.1% reduction with placebo

At the 12 mg target dose, the average weight reduction had not clearly reached a plateau by week 48. This suggested that average weight was still decreasing when the trial ended.

These are group averages from a controlled clinical trial. They do not mean that every participant lost the same amount.

Results varied, and some participants discontinued treatment or experienced adverse effects.

The Phase 2 trial also examined how many participants lost at least 5%, 10%, 15% or 20% of their starting body weight.

At 48 weeks, a substantial proportion of participants in the higher-dose groups reached the larger thresholds.

In the 12 mg group:

• Nearly all participants reached at least 5% weight loss

• More than nine in ten reached at least 10%

• More than eight in ten reached at least 15%

• More than six in ten reached at least 20%

These figures helped generate interest in RT GLP3, but they should be interpreted within the trial’s limitations.

The study lasted 48 weeks, involved a defined participant population and was not designed to answer every question about long-term use, maintenance or uncommon adverse effects.

What has Phase 3 research reported?

RT GLP3 has progressed into an extensive Phase 3 development programme.

Phase 3 trials are larger studies intended to provide stronger evidence about effectiveness and safety across relevant patient groups.

The programme includes research in areas such as:

• Obesity and overweight

• Type 2 diabetes

• Obesity with cardiovascular disease

• Obstructive sleep apnoea

• Knee osteoarthritis

• Cardiovascular and kidney outcomes

• Weight-loss maintenance

In May 2026, Lilly announced preliminary headline results from the TRIUMPH-1 Phase 3 obesity trial.

According to the company’s announcement, participants assigned to the 12 mg dose lost an average of 28.3% of their starting body weight over 80 weeks under the trial’s stated efficacy analysis. The company also reported that 45.3% reached at least 30% weight loss.

These figures were released by the manufacturer and should be distinguished from a complete peer-reviewed publication.

Detailed analysis is needed to understand:

• The full statistical methods

• Results under different estimands

• Missing-data handling

• Treatment discontinuations

• Outcomes across participant subgroups

• The complete adverse-event profile

• How results compare with existing treatments

The announcement is important, but headline percentages should not be treated as the final scientific assessment of the trial.

What has research found in type 2 diabetes?

RT GLP3 has also been studied in adults with type 2 diabetes.

A Phase 2 trial compared several RT GLP3 doses with placebo and dulaglutide over 36 weeks.

Researchers investigated:

• HbA1c

• Fasting glucose

• Body weight

• Safety

• Adverse events

HbA1c reflects average blood-glucose exposure over approximately two to three months.

The Phase 2 results showed clinically meaningful reductions in HbA1c and body weight. These findings helped researchers choose dose ranges for the Phase 3 programme.

In March 2026, Lilly announced preliminary results from TRANSCEND-T2D-1, the first Phase 3 RT GLP3 trial in type 2 diabetes.

The company reported average HbA1c reductions of approximately 1.7 to 2.0 percentage points across the studied doses at 40 weeks. It also reported an average body-weight reduction of 16.8% in the 12 mg group.

As with the preliminary obesity announcement, full peer-reviewed publication is necessary before the results can be assessed in complete detail.

RT GLP3 and liver fat

Excess fat stored in the liver is closely associated with insulin resistance and metabolic dysfunction.

A substudy of the Phase 2 obesity trial investigated RT GLP3 in participants with metabolic dysfunction-associated steatotic liver disease, or MASLD, and elevated liver fat.

Researchers used imaging to measure changes in liver-fat content.

Large average reductions in liver fat were observed, particularly in the higher-dose groups. Many participants moved below commonly used thresholds for steatosis during the study.

These findings are scientifically important because they suggest that RT GLP3’s effects may extend beyond total body weight.

However, reducing liver fat is not identical to proving that a treatment reverses liver inflammation or fibrosis.

Longer and more specialised trials are required to determine its clinical role in metabolic liver disease.

Does RT GLP3 cause fat loss or muscle loss?

Weight loss usually includes a combination of:

• Fat mass

• Lean tissue

• Water

• Other body components

A body-composition substudy in participants with type 2 diabetes found that RT GLP3 produced substantial reductions in total fat mass.

Lean mass also decreased, as commonly occurs during significant weight loss. However, the proportion of total weight loss coming from lean mass was reported to be broadly similar to that observed with other obesity treatments.

This does not mean muscle preservation is guaranteed.

“Lean mass” is not exactly the same as skeletal muscle, and body-composition measurements do not reveal strength, physical function or nutritional status on their own.

The long-term effects of very large medication-associated weight reductions on muscle, bone health and physical function remain important areas of research.

What other effects are researchers studying?

RT GLP3 research extends beyond body weight alone.

Clinical programmes are examining whether treatment affects conditions that are associated with obesity or metabolic dysfunction.

Waist circumference provides an approximate indication of central fat distribution.

Phase 2 research reported reductions in waist circumference alongside reductions in body weight.

Improvements in blood pressure and lipid measurements were observed in clinical research.

It is not yet possible to assume that changes in these risk markers will automatically produce a specific reduction in heart attacks, strokes or cardiovascular deaths.

Dedicated outcomes trials are required for that purpose.

Obstructive sleep apnoea is more common in people with obesity, partly because fat distribution can contribute to narrowing or collapse of the upper airway during sleep.

Phase 3 research is assessing whether RT GLP3-associated weight reduction improves measures such as the apnoea-hypopnoea index.

Excess body weight can increase the mechanical load placed on weight-bearing joints. Metabolic and inflammatory factors may also contribute to osteoarthritis symptoms.

Clinical trials are investigating whether RT GLP3 can improve knee pain and physical function in people with obesity or overweight and knee osteoarthritis.

Improvement could result from reduced mechanical load, metabolic changes or a combination of factors.

Large trials are investigating whether RT GLP3 affects major cardiovascular events or worsening kidney disease in higher-risk populations.

These studies are important because changes in weight, HbA1c or blood pressure do not necessarily prove long-term protection against major clinical events.

What adverse effects have been reported?

The most frequently reported adverse effects in RT GLP3 trials have involved the gastrointestinal system.

These have included:

• Nausea

• Diarrhoea

• Vomiting

• Constipation

• Reduced appetite

• Abdominal discomfort

Digestive effects were generally more common at higher doses and during dose escalation.

Clinical trials used staged escalation schedules rather than beginning all participants immediately at the final target dose. This allowed researchers to investigate whether gradual increases improved tolerability.

Some participants discontinued treatment because of adverse events.

Phase 2 research reported dose-dependent increases in heart rate.

Average heart rate appeared to peak during the treatment period and later decline from that peak, although it did not necessarily return fully to baseline in every group before the study ended.

The clinical importance of this finding requires continued evaluation, particularly in people with cardiovascular disease.

This is one reason longer and larger trials are necessary even when early weight-loss results appear encouraging.

RT GLP3’s incretin-related insulin effects are glucose dependent, which may limit the risk of hypoglycaemia when the compound is used alone.

However, the risk can change when glucose-lowering treatments are combined, particularly insulin or medicines that independently stimulate insulin secretion.

Trials in people with diabetes monitor hypoglycaemic events carefully.

The risk profile from a controlled trial should not be applied to unregulated products with uncertain identity or concentration.

Clinical trials are designed to monitor a wide range of safety outcomes, but early studies cannot reliably identify every uncommon or delayed adverse effect.

Questions requiring continued investigation include:

• Gallbladder-related events

• Pancreatic safety

• Cardiovascular effects

• Severe gastrointestinal complications

• Kidney injury related to dehydration

• Consequences of substantial or rapid weight reduction

• Long-term effects on lean mass and bone health

• Weight regain after discontinuation

• Safety across different medical populations

Absence of a strong signal in a relatively short trial does not prove that a rare risk does not exist.

Is RT GLP3 approved in the UK?

No.

As of July 2026, RT GLP3 remains an investigational medicine and has not been approved by the Medicines and Healthcare products Regulatory Agency for routine use in the United Kingdom.

It does not currently have an approved UK prescribing indication, licensed retail product or authorised patient dosing instructions.

The existence of Phase 3 results or regulatory-development activity does not mean a medicine has been approved.

Clinical development, regulatory submission and marketing authorisation are separate stages.

Frequently asked questions

It activates the GLP-1 receptor, but that is only one part of its mechanism.

RT GLP3 also activates GIP and glucagon receptors. Calling it only a GLP-1 receptor agonist leaves out two defining components.

No.

TZ GLP1 activates GIP and GLP-1 receptors. RT GLP3 activates GIP, GLP-1 and glucagon receptors.

They are separate molecules with different receptor profiles and clinical evidence.

No.

Semaglutide is a GLP-1 receptor agonist. RT GLP3 is a triple GIP, GLP-1 and glucagon receptor agonist.

No.

RT GLP3 is not insulin. It can influence glucose-dependent insulin secretion through its incretin-receptor activity, but it does not replace insulin itself.

It is called a triple agonist because one molecule activates three receptor systems: GIP, GLP-1 and glucagon.

Reduced appetite has been reported during clinical trials.

Its overall effect is more complex than appetite suppression alone because it may also influence glucose regulation, gastric emptying, energy expenditure and fat metabolism.

The glucagon component is being investigated partly because glucagon-receptor activation may influence energy expenditure and fat oxidation.

However, RT GLP3 should not be described simply as a “metabolism booster.” Human weight change results from its combined multi-receptor effects.

Clinical trials have generally investigated once-weekly administration.

This schedule is supported by its reported half-life of approximately six days.

This is a description of clinical research, not an instruction for personal use.

Weight reduction developed progressively over the course of clinical trials.

In the Phase 2 obesity study, average reductions continued between weeks 24 and 48 in the higher-dose groups. Preliminary Phase 3 findings have assessed outcomes over longer periods.

Results cannot predict how any individual would respond.

No.

Published percentages represent averages or proportions within groups. Individual responses varied.

Some participants lost more, some lost less, and some stopped treatment.

A Phase 3 head-to-head trial comparing RT GLP3 with TZ GLP1 in adults with obesity has been registered.

Complete results are not yet available, so claims that one is definitively superior should be treated cautiously.

Clinical trials assess treatment within a structured research setting, often including lifestyle guidance.

The results do not show that nutrition, physical activity, sleep and wider health behaviours become irrelevant.

Long-term maintenance and withdrawal effects remain under investigation.

Experience with other obesity medicines suggests that biological pressures favouring weight regain can return after treatment stops, but RT GLP3-specific maintenance evidence is still developing.

Yes.

It has been studied in type 2 diabetes and has progressed into a Phase 3 diabetes programme.

It is not approved as a diabetes medicine at the time of writing.

Researchers have examined changes in liver fat, and substantial reductions were reported in a Phase 2 substudy.

Further evidence is required to establish its effect on liver inflammation, fibrosis and long-term clinical outcomes.

No.

Although several important trials have reported results, other Phase 3 studies and longer-term outcomes studies remain ongoing.

Regulators must assess the complete evidence package before deciding whether to grant approval.

No guaranteed UK release date has been confirmed.

Lilly has indicated plans to seek regulatory review, but submission does not guarantee approval. Timing depends on trial completion, regulatory assessment, manufacturing requirements and the final benefit-risk evaluation.

Clinical trials have produced an expanding safety dataset, with gastrointestinal effects among the most frequently reported adverse events.

However, “safe” is not an absolute description. Safety depends on the population, medical history, dose, product quality, monitoring, duration and comparison between benefits and risks.

RT GLP3 remains investigational because this assessment is not complete.

Key points

RT GLP3 is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors.

Its GLP-1 and GIP activity supports appetite and glucose-regulation pathways, while its glucagon activity may influence energy expenditure, fat oxidation and liver metabolism.

Phase 2 trials reported substantial average reductions in body weight, alongside improvements in HbA1c and several cardiometabolic measurements.

Preliminary Phase 3 company announcements have reported larger average weight reductions over longer treatment periods. Complete peer-reviewed publications are still important for evaluating these results fully.

Gastrointestinal adverse effects have been common, and changes in heart rate have also been observed.

RT GLP3 is not the same as semaglutide or TZ GLP1, and receptor count alone cannot determine which treatment is safest or most suitable.

As of July 2026, RT GLP3 is not approved for routine medical use in the United Kingdom.

Glossary

Agonist: A substance that binds to and activates a receptor.

Clinical trial: A controlled study conducted in human participants to investigate a medical intervention.

GIP: Glucose-dependent insulinotropic polypeptide, an incretin hormone involved in insulin secretion and nutrient metabolism.

GLP-1: Glucagon-like peptide-1, an incretin hormone involved in appetite, insulin secretion, gastric emptying and glucose regulation.

Glucagon: A hormone involved in maintaining energy availability, including signalling the liver to release glucose.

HbA1c: A blood measurement used to estimate average glucose exposure over approximately two to three months.

Half-life: The approximate time required for the amount of a substance in the body to decrease by half.

Incretin: A gut-derived hormone that supports the insulin response to nutrients.

Investigational medicine: A substance being evaluated in clinical research that has not yet received approval for routine use.

MASLD: Metabolic dysfunction-associated steatotic liver disease, a condition involving excess liver fat associated with metabolic risk.

Peptide: A chain of amino acids. Peptides can act as hormones, signalling molecules or medicines.

Phase 2 trial: A study that investigates effectiveness, dose response and common adverse effects in a selected participant population.

Phase 3 trial: A larger study designed to provide more definitive evidence about effectiveness and safety before potential regulatory approval.

Receptor: A cellular structure that responds to a specific biological signal.

This article is provided for general scientific and educational purposes. It does not constitute medical advice, prescribing guidance or instructions for human use.

RT GLP3 remains an investigational medicine and is not approved for routine medical use in the United Kingdom. Research materials must not be used as substitutes for authorised medicines or administered to humans.